Information is now available for weight-loss drugs Belviq and Qsymia on Phentermine-375.net website.
/EINPresswire.com/Phentermine-375.net is a website dedicated to providing information to users regarding prescription weight loss pills, particularly generic and trade brand phentermine 37.5mg diet pills. In addition, Phentermine-375.net provides weight loss tools and tips for dieters. In the determination of being fully informative, Phentermine-375.net has added information regarding the two most recently approved FDA weight loss drugs Belviq and Qsymia. Both pills were initially denied approval pending further research. Currently Qsymia is approved and available for prescription only use, whereas Belviq has secured FDA approval, it must undergo further 4-6 months analysis before doctors have the go ahead to begin prescribing.
Qsymia, made by Vivus Inc. combines two existing drugs phentermine / topiramate. Phentermine is an appetite suppressant used for short term weight loss. Ttopiramate is an anti-seizure drug that has been found to make users feel fuller after eating.
Both weight loss pills are only available with a doctor’s prescription and are approved for obese patients with a body mass index (BMI) of 30 or higher and overweight people, with a BMI of 27 or higher. In addition, patients must also have at least one weight-related condition like high blood pressure or diabetes in order to use Qsymia or Belviq.
Belviq is made by Arena Pharmaceuticals and is formulated with the drug Iorcaserin. It will be distributed by Eisai Co. Ltd. However, Belviq is not currently available for sale. The drug has to undergo a four-to-six month process by the Drug Enforcement Administration for a scheduling classification used for drugs that have the possibility of being abused. Once this procedure has been completed, Eisai will announce Belviq’s pricing and when the drug will finally become available.
For more weight loss pill information, visit Phentermine-375.net.
For more weight loss pill information, visit Phentermine-375.net.
Media Contact:
Jennifer Hughs
jenniferhughs@gmail.com
http://phentermine-375.net/
PR courtesy of Online PR Media.
